ROLE SUMMARY The Lung cancer portfolio is one of the fastest growing portfolios in Pfizer Oncology and includes the following brands: LORBRENA and BRAFTOVI/MEKTOVI Lung. Lung cancer is the most common cancer, and LORBRENA, our ALK+ inhibitor has been prescribed to over 12,000 patients since launching in the US in 2018. The practice-changing 5-year follow-up data from ASCO 2024 has led to 40% growth in 2025 and has solidified LORBRENA’s position in treating patients with ALK+ metastatic non-small cell lung cancer (NSCLC). We anticipate additional follow-up analysis of the pivotal Phase 3 CROWN trial data to be presented later this year to further strengthen the medicine’s position in the current treatment paradigm. The Director LORBRENA/Lung Marketing position will report to the US Lung Team Lead and will be responsible for the following: 1. leading the development of LORBRENA’s non-personal HCP strategy, 2. Co-creating promotional strategy and tactics with the LORBRENA HCP strategy lead, 3. working across the lung portfolio to lead non-personal promotional analytics and engagement. Activities associated with this position include strategic marketing, tactical planning, data & analytics. The Director will work closely with internal and external partners, including, CMO, media, market analytics, Regulatory, Legal, Medical Affairs, TLELs, Advocacy, other members of the brand team, and agencies.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
5,001-10,000 employees